safeti
import
consider
ad
vaccin
develop
given
case
asept
meningoenceph
observ
previous
clinic
trial
like
associ
autoreact
cell
infiltr
brain
vaccin
subject
avoid
risk
develop
multitep
vaccin
platform
consist
string
nonself
pathogenderiv
helper
th
epitop
attach
differ
b
cell
selfepitop
neuron
protein
involv
ad
pathogenesi
previous
demonstr
dna
vaccin
compos
three
copi
b
cell
epitop
ntermin
region
attach
multitep
protein
highli
immunogen
mice
rabbit
macaqu
develop
vaccin
target
patholog
tau
decid
use
immunogen
multitep
platform
incorpor
tau
epitop
chose
epitop
previous
shown
tau
normal
hidden
microtubul
bound
tau
conform
becom
highli
expos
tau
aggreg
importantli
region
tau
also
term
phosphataseactiv
domain
pad
play
import
role
activ
signal
cascad
involv
lead
dissoci
cargo
kinesin
therefor
anterograd
fast
axon
transport
fat
inhibit
exposur
pad
requir
inhibit
fat
might
regul
pad
phosphoryl
well
ntermin
truncat
tau
occur
neurofibrillari
tangl
format
phosphoryl
well
truncat
ntermin
region
aggreg
tau
suggest
remov
toxic
region
protect
role
thu
hypothes
antitau
antibodi
preferenti
recogn
patholog
rather
normal
form
tau
therebi
prevent
aggreg
pad
mediat
toxic
earli
stage
tauopathi
describ
first
time
gener
mutitep
platformbas
recombin
vaccin
target
tau
tau
simultan
dual
specif
report
immunogen
vaccin
also
identifi
novel
adjuv
advax
cpg
deriv
delta
inulin
provid
optim
immun
enhanc
mutitep
vaccin
show
high
antibodi
titer
correl
reduct
brain
patholog
immun
ad
patient
later
came
autopsi
suggest
therapeut
benefit
close
link
antibodi
titer
cgmp
grade
delta
inulinbas
adjuv
advax
advax
cpg
previous
report
enhanc
immunogen
efficaci
variou
vaccin
target
viral
bacteri
antigen
preclin
studi
clinic
trial
select
adjuv
induc
highest
antibodi
respons
lowest
variabl
antibodi
level
respons
vaccin
mice
test
adjuv
parallel
quila
less
purifi
version
adjuv
use
clinic
trial
well
commerci
adjuv
alhydrogel
mplasm
result
show
formul
advax
cpg
induc
significantli
stronger
antibodi
respons
adjuv
low
variabl
respons
anim
advax
cpg
group
fig
analysi
antibodi
isotyp
specif
show
alhydrogel
advax
tm
adjuv
induc
primarili
respons
wherea
advax
cpg
mpla
quila
shift
respons
toward
b
respons
associ
isotyp
fig
explor
adjuv
effect
phenotyp
measur
number
splenocyt
produc
cytokin
elispot
spotform
cell
sfc
found
advax
cpg
group
produc
significantli
higher
frequenc
th
cell
adjuv
group
fig
b
agonist
mpla
gmpgrade
adjuv
gener
signific
number
th
cell
although
approxim
time
respect
lower
induc
advax
cpg
fig
b
calcul
ratio
posit
th
cell
fig
support
antibodi
isotyp
data
confirm
advax
cpg
strongest
combin
adjuv
follow
mpla
adjuv
gener
primarili
respons
immun
level
respons
induc
control
adjuv
quila
compar
mpla
significantli
lower
advax
cpg
fig
final
advax
cpg
also
well
toler
anim
evid
either
local
system
vaccin
advers
reaction
basi
data
advax
cpg
select
sole
adjuv
subsequ
studi
multitepbas
ad
vaccin
target
tau
tau
simultan
sequenti
immunogen
efficaci
differ
ad
vaccin
formul
advax
cpg
adjuv
test
ad
vaccin
formul
advax
cpg
adjuv
gener
equal
strong
cell
respons
measur
detect
sfc
splenocyt
prolifer
specif
foreign
th
cell
epitop
incorpor
multitep
platform
fig
note
potenti
harm
autoreact
th
cell
detect
restimul
immun
splenocyt
tau
selfepitop
either
elispot
splenocyt
prolifer
assay
data
shown
importantli
gener
strong
cellular
immun
respons
th
epitop
incorpor
multitep
vaccin
platform
support
product
equal
high
concentr
antibodi
mice
vaccin
combin
expect
immun
gener
antibodi
fig
mention
concentr
antitau
antibodi
significantli
lower
mice
immun
compar
mice
vaccin
combin
alon
fig
antibodi
respons
pattern
mirror
frequenc
antibodi
secret
b
cell
asc
number
asc
similar
mice
immun
singl
combin
vaccin
formul
number
antitau
asc
significantli
lower
mice
vaccin
dualepitop
vaccin
fig
hypothes
antitau
b
cell
epitop
attach
multitep
may
well
present
surfac
dualepitop
vaccin
compar
singl
epitop
construct
address
possibl
undertook
silico
structur
model
multitep
platformbas
vaccin
examin
surfac
access
b
cell
antigen
determin
efrh
tau
prqef
paper
prepar
fig
model
data
suggest
two
three
tau
epitop
linear
side
chain
critic
amino
acid
residu
access
surfac
fig
three
epitop
linear
side
chain
critic
amino
acid
residu
access
surfac
fig
e
two
three
two
three
tau
epitop
linear
howev
side
chain
critic
tau
amino
acid
residu
easili
access
fig
f
henc
chang
epitop
structur
combin
alter
side
chain
access
critic
residu
epitop
may
led
reduc
antitau
immunogen
dualepitop
construct
demonstr
effect
antibodi
gener
mice
immun
singl
vaccin
mixtur
two
vaccin
dual
vaccin
analyz
bind
immun
sera
variou
patholog
form
tau
brain
tissu
four
differ
ad
case
western
blot
wb
fig
b
immunohistochemistri
ihc
fig
sera
bound
monomer
solubl
well
low
high
molecular
weight
oligom
solubl
insolubl
fraction
brain
homogen
expect
sera
recogn
monomer
tau
well
multipl
larger
smaller
speci
tau
solubl
insolubl
fraction
brain
homogen
import
antibodi
gener
either
mixtur
vaccin
dual
vaccin
recogn
speci
tau
detect
antisera
isol
mice
vaccin
appropri
singl
vaccin
similar
result
obtain
ihc
analys
brain
tissu
fig
sera
bound
senil
plaqu
sera
bound
nft
neurit
thread
yet
sera
mice
immun
mixtur
bound
patholog
plaqu
neurit
thread
nft
therefor
mixtur
multitepplatform
base
vaccin
dual
vaccin
could
effect
activ
immunotherapeut
strategi
target
misfold
protein
involv
ad
patholog
b
ratio
calcul
bar
repres
averag
sd
n
per
group
statist
signific
calcul
group
mice
immun
formul
advax
cpg
use
anova
test
p
p
p
scientif
report
doi
cross
synerg
multitepbas
vaccin
target
differ
antigen
vaccin
base
univers
multitep
vaccin
platform
base
string
th
foreign
epitop
shown
monkey
stimul
immun
respons
broad
popul
subject
high
mhc
class
ii
gene
polymorph
notabl
univers
multitep
platform
may
allow
use
two
vaccin
target
tau
earli
late
stage
diseas
respect
initi
antitau
immunotherapi
ad
patient
immun
previous
vaccin
would
larg
number
multitepspecif
memori
th
cell
henc
rapidli
gener
therapeut
concentr
antibodi
simul
situat
immun
mice
formul
advax
cpg
inject
advax
cpg
control
group
boost
vaccin
target
tau
b
cell
epitop
boost
vaccin
mice
shaminject
mice
induc
significantli
higher
cellular
fig
humor
fig
immun
respons
thu
prove
synergist
effect
sequenti
immun
differ
multitep
vaccin
bar
repres
averag
sd
n
group
statist
signific
calcul
group
mice
immun
formul
advax
cpg
use
anova
test
p
p
p
p
scientif
report
doi
discuss
ad
common
caus
dementia
worldwid
nearli
million
peopl
alzheim
relat
dementia
number
estim
increas
million
current
major
neuroscientist
agre
optim
target
ad
immunotherapi
patholog
form
tau
relationship
molecul
progress
ad
patholog
still
controversi
major
data
support
aggreg
primari
event
ad
pathogenesi
secondarili
trigger
product
patholog
tau
nonetheless
accumul
patholog
tau
brain
correl
dementia
ad
patient
thu
time
clinic
symptom
appear
alreadi
substanti
tau
patholog
brain
therefor
propos
immunotherapi
initi
earli
stage
ad
minim
synapt
neuron
loss
antitau
immunotherapi
may
effect
diseas
progress
advanc
thu
decid
gener
vaccin
target
patholog
molecul
either
sequenti
eg
vaccin
follow
tau
vaccin
simultan
mixtur
plu
tau
vaccin
dualepitop
vaccin
contain
tau
b
cell
epitop
importantli
although
clinic
data
antitau
immunotherapi
current
avail
result
activ
passiv
vaccin
trial
suggest
rel
high
concentr
antibodi
therapeut
potent
therefor
enhanc
immun
respons
elderli
patient
immunosenesc
develop
recombin
proteinbas
tau
dualepitop
vaccin
fuse
relev
epitop
patholog
protein
multitep
platform
compos
foreign
th
cell
epitop
promiscu
padr
epitop
epitop
tetanu
toxin
hepat
b
hbvnc
hbsag
influenza
viru
mt
hypothes
provid
broad
coverag
human
mhc
class
ii
polymorph
util
wide
array
tetanu
toxin
hepat
b
influenza
th
epitop
incorpor
multitep
platform
previous
shown
multitep
platformbas
dna
vaccin
target
immunogen
mice
rabbit
monkey
highli
polymorph
mhc
class
ii
gene
suggest
multitep
platform
use
two
differ
recombin
proteinbas
vaccin
target
tau
could
benefici
th
cell
activ
gener
strong
th
memori
cell
facilit
rapid
product
antitau
antibodi
futur
vaccin
organ
antitau
vaccin
studi
report
first
time
immunogen
vaccin
target
tau
patholog
molecul
simultan
sequenti
well
known
immunogen
recombin
protein
formul
potent
adjuv
trial
substanti
portion
vaccin
subject
nonrespond
even
though
strong
adjuv
use
thu
first
aim
studi
identifi
optim
adjuv
use
futur
ad
vaccin
trial
figur
clearli
demonstr
advax
cpg
formul
vaccin
provid
significantli
higher
th
cell
antibodi
respons
adjuv
approv
human
use
test
clinic
trial
moreov
advax
cpg
enhanc
immun
respons
reflect
highest
induct
also
b
antibodi
isotyp
antibodi
b
isotyp
exhibit
highest
level
fc
effector
function
may
provid
utmost
effici
ad
immunotherapi
acut
proinflammatori
respons
sfc
gener
formul
advax
cpg
could
benefici
ad
treatment
well
sinc
agonist
mpla
reduc
load
brain
mice
enhanc
cognit
function
final
multitepbas
vaccin
design
anticip
safe
th
epitop
platform
foreign
express
brain
first
report
advax
cpg
use
enhanc
immun
respons
b
cell
selfepitop
fuse
multitep
potenc
adjuv
previous
demonstr
vaccin
target
viral
bacteri
antigen
importantli
pandem
influenza
vaccin
formul
advax
effect
human
subject
year
age
enhanc
antiinfluenza
plasmablast
antibodi
respons
across
whole
age
spectrum
abil
deltainulin
base
adjuv
help
counter
normal
agerel
declin
plasmablast
antibodi
respons
influenza
immun
like
import
human
ad
vaccin
develop
princip
need
administ
elderli
subject
immunosenesc
mention
differ
time
tau
accumul
differ
role
onset
progress
ad
suggest
sequenti
vaccin
tau
vaccin
even
combin
vaccin
molecul
might
repres
effect
ad
approach
particular
vaccin
platform
could
use
prevent
onset
ad
also
slow
develop
tauopathyassoci
dementia
order
util
approach
develop
three
multitep
platformbas
vaccin
target
tau
molecul
simultan
multitepbas
vaccin
formul
advax
cpg
induc
strong
cellular
humor
concentr
antibodi
number
asc
immun
respons
fig
coimmun
vaccin
provid
high
antibodi
titer
tau
epitop
respect
humor
immun
respons
differ
result
immun
singl
vaccin
howev
dual
vaccin
demonstr
significantli
decreas
antitau
humor
immun
respons
compar
mice
immun
mixtur
vaccin
fig
decreas
antibodi
titer
number
asc
associ
insuffici
th
cell
stimul
vs
sinc
th
cell
respons
differ
significantli
group
fig
suggest
three
copi
tau
b
cell
epitop
multitep
vaccin
might
adequ
present
surfac
fold
protein
absenc
crystal
structur
perform
silico
approach
creat
structur
model
multitepbas
protein
optim
use
scientif
report
doi
molecular
dynam
simul
silico
model
vaccin
appear
tau
epitop
may
less
optim
present
surfac
dual
vaccin
singl
one
fig
subtl
differ
structur
configur
may
play
critic
role
observ
differ
antibodi
titer
asc
number
anoth
possibl
reason
could
b
cell
immunodomin
epitop
may
suppress
matur
tauspecif
b
cell
competit
antigenspecif
th
cell
howev
case
immun
perform
mixtur
two
vaccin
contain
th
epitop
fig
addit
perform
experi
increas
dose
see
increas
antitau
antibodi
concentr
data
shown
regardless
exact
caus
vari
immunogen
seen
differ
multitepbas
tau
vaccin
clear
vaccin
immunogen
dualepitop
vaccin
therefor
could
use
ad
therapi
follow
prevent
vaccin
mice
prime
respond
significantli
better
booster
vaccin
fig
b
importantli
regardless
vaccin
use
singl
mixtur
dual
gener
antibodi
potenti
function
bind
equal
well
patholog
deposit
tau
brain
section
four
ad
case
fig
import
note
antibodi
effect
bind
oligomer
form
tau
wide
believ
much
toxic
fibril
plaqu
data
may
open
new
avenu
futur
vaccin
regimen
prevent
could
use
prodrom
ad
subject
case
subsequ
diseas
progress
boost
could
perform
vaccin
henc
use
prevent
vaccin
ad
onset
ad
may
provid
broadest
protect
across
ad
clinic
diseas
spectra
summari
optim
ad
vaccin
formul
adjuv
select
target
right
epitop
appropri
stage
diseas
crucial
success
immunotherapeut
approach
ad
vaccin
base
target
epitop
attach
univers
highli
immunogen
multitep
vaccin
platform
combin
advax
cpg
potent
yet
well
toler
adjuv
suitabl
human
use
induc
extrem
high
antibodi
titer
tau
level
previous
achiev
studi
multitep
strategi
provid
uniqu
opportun
gener
high
antibodi
respons
subject
util
memori
th
cell
previous
gener
human
popul
respons
infect
vaccin
tetanu
toxin
hepat
b
influenza
multitep
platform
may
especi
benefici
elderli
vaccin
util
memori
cell
abund
elderli
patient
instead
reli
activ
cell
declin
age
therefor
univers
highli
immunogen
multitep
vaccin
platform
show
promis
prevent
therapeut
approach
ad
mice
femal
week
old
mice
b
haplotyp
obtain
jackson
laboratori
anim
hous
temperatur
lightcycl
control
facil
care
guidelin
nih
approv
iacuc
protocol
uc
irvin
anim
experi
perform
accord
prepar
three
recombin
protein
minigen
encod
multitep
multitep
clone
modifi
e
coli
express
vector
novagen
novagen
frame
cterminu
dna
sequenc
perform
confirm
gener
plasmid
contain
correct
sequenc
brain
homogen
contain
g
total
protein
four
ad
case
stain
immun
sera
normal
gml
gml
antitau
antibodi
base
elisa
data
c
immun
sera
screen
abil
bind
human
plaqu
orand
tau
tangl
use
brain
section
formalinfix
cortic
tissu
ad
case
origin
magnif
scale
bar
scientif
report
doi
purif
protein
recombin
protein
purifi
e
coli
cell
transform
multitep
multitep
plasmid
describ
final
recombin
protein
analyz
bistri
gel
electrophoresi
nupag
novex
gel
invitrogen
ca
protein
band
visual
coomassi
dye
fig
specif
band
confirm
western
blot
wb
use
fig
antitau
fig
inject
four
time
biweekli
interv
sera
collect
day
third
immun
use
measur
antibodi
respons
day
last
inject
mice
termin
cellular
immun
respons
analyz
splenocyt
four
group
mice
n
per
group
immun
gper
mousep
inject
multitep
gper
mousep
inject
gper
mousep
inject
mixtur
protein
g
proteinmouseinject
formul
advax
cpg
adjuv
mgmous
inject
control
group
mice
inject
advax
cpg
adjuv
pb
n
group
mice
inject
four
time
biweekli
interv
sera
collect
day
third
immun
antitau
antibodi
respons
analyz
day
last
inject
mice
termin
cellular
immun
respons
analyz
splenocyt
studi
effect
switch
two
group
mice
n
immun
twice
formul
advax
cpg
inject
advax
cpg
group
receiv
singl
vaccin
formul
advax
cpg
four
mice
group
termin
day
third
inject
cell
respons
measur
splenocyt
remain
mice
n
per
group
bled
day
immun
measur
serum
antibodi
respons
detect
tauspecif
antibodi
concentr
antitau
antibodi
serum
determin
elisa
describ
previous
antitau
antibodi
concentr
calcul
use
calibr
curv
gener
covanc
ca
mab
gener
institut
molecular
medicin
huntington
beach
ca
respect
hrpconjug
antimous
igg
jackson
immunoresearch
laboratori
use
secondari
antibodi
hrpconjug
b
igm
specif
antibodi
bethyl
laboratori
inc
use
character
isotyp
profil
antibodi
individu
sera
differ
dilut
see
legend
fig
produc
cell
perform
splenocyt
cultur
immun
mice
elispot
assay
bd
bioscienc
ca
previous
describ
cultur
splenocyt
restimul
vitro
cocktail
peptid
repres
th
epitop
multitep
vaccin
gml
peptid
solubl
tau
irrelev
peptid
gml
hour
number
sfc
per
splenocyt
stimul
th
peptid
tau
count
cell
prolifer
assay
perform
splenocyt
cultur
use
h
thymidin
incorpor
assay
previous
describ
cultur
splenocyt
mice
restimul
vitro
antigen
use
elispot
assay
stimul
index
si
calcul
mous
use
formula
si
experiment
countspontan
count
spontan
count
well
includ
irrelev
peptid
specif
tau
detect
splenocyt
elispot
mabtech
inc
cincinnati
oh
splenocyt
experiment
control
mice
incub
hour
plate
coat
tau
peptid
incub
assay
perform
recommend
manufactur
mabtech
inc
cincinnati
oh
prepar
brain
homogen
western
blot
analysi
solubl
insolubl
fraction
g
brain
tissu
four
differ
ad
case
homogen
ml
tb
buffer
halt
proteas
phosphatas
inhibitor
cocktail
thermo
scientif
ca
centrifug
minut
supernat
collect
store
analysi
solubl
fraction
remain
pellet
solubil
formic
acid
fa
centrifug
g
hr
avoid
upper
lipid
layer
lower
aqueou
layer
collect
store
later
quantif
insolubl
tau
level
prior
next
step
fa
fraction
neutral
sodium
hydroxid
naoh
follow
neutral
buffer
tri
base
nah
po
precipit
ice
cold
trichloroacet
acid
tca
aceton
precipit
fraction
resolubil
equal
volum
tb
protein
concentr
determin
use
bca
protein
assay
kit
pierc
il
sampl
adjust
equal
concentr
western
blot
wb
solubl
insolubl
fraction
four
brain
homogen
perform
describ
briefli
solubl
insolubl
fraction
appli
electrophoresi
nupag
bistri
gel
me
buffer
reduc
condit
invitrogen
ca
electrotransf
onto
nitrocellulos
membran
ge
healthcar
nj
antigen
retriev
membran
solubl
fraction
boil
pb
describ
rosen
et
al
block
fatfre
dri
milk
membran
insolubl
fraction
block
without
antigen
retriev
tau
visual
incub
sera
mice
immun
mixtur
follow
hrpconjug
antimous
igg
santa
cruz
biotechnolog
ca
sera
use
normal
antibodi
concentr
measur
elisa
gml
gml
antitau
detect
plaqu
tau
tangl
human
brain
tissu
ihc
sera
mice
immun
mixtur
screen
abil
bind
human
plaqu
orand
tau
tangl
use
brain
section
formalinfix
cortic
tissu
four
differ
sever
ad
case
receiv
brain
bank
tissu
repositori
mind
uc
irvin
use
immunohistochemistri
describ
previous
digit
camera
olympu
tokyo
japan
use
captur
imag
plaqu
magnif
multitep
protein
submit
psipr
protein
structur
predict
server
fold
profil
base
thread
templat
structur
match
fold
pattern
queri
pvalu
select
individu
templat
use
appropri
refer
provid
supplementari
tabl
base
multipl
sequenc
align
queri
templat
homolog
model
gener
use
homolog
model
program
model
homolog
model
evalu
refin
select
base
discret
optim
protein
energi
score
dope
model
relax
use
molecular
dynam
simul
program
namd
step
k
temperatur
final
model
synthet
multitep
protein
contain
tau
epitop
combin
visual
use
molecular
model
program
ucsf
chimera
statist
analysi
statist
paramet
mean
standard
deviat
sd
signific
differ
etc
calcul
use
prism
softwar
graphpad
softwar
inc
la
jolla
ca
statist
signific
differ
examin
use
ttest
analysi
varianc
anova
tukey
multipl
comparison
posttest
p
valu
less
consid
signific
